Clinical Trials Logo

Macular Edema clinical trials

View clinical trials related to Macular Edema.

Filter by:

NCT ID: NCT05978622 Recruiting - Clinical trials for Diabetic Macular Edema

Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

Start date: October 30, 2023
Phase:
Study type: Observational

The dexamethasone 700 μg intravitreal implant (DEX-I) delivers dexamethasone gradually to the retina over time. It is an approved drug for the treatment of DME. This study will assess adult participants with diabetic macular edema (DME) and suboptimal response to anti-vascular endothelial growth factor therapy that are treated with DEX-I in the routine clinical setting. Approximately 327 participants who are prescribed DEX-I by their physicians will be enrolled at approximately 40 sites in approximately 10 countries globally. Participants will be followed for 18 months post-DEX-I implantation according to the routine clinical practice of the prescribing centers. Only one eye per participant will be evaluated in the study. No additional burden for participants in this trial is expected.

NCT ID: NCT05976139 Recruiting - Macular Edema Clinical Trials

Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies

Start date: September 6, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether subthreshold treatment with micropulsed laser can be effective in resolving macular edema in patients with inherited retinal dystrophy. Visits will be performed after 1, 3, 6, 9, 12, 18, and 24 months after treatment. Laser treatment will be performed on the day of the first visit, and its repetition at subsequent visits between months 3 and 12 will be evaluated. Evaluations of treatment effects will include: - comprehensive ophthalmologic examination - multifocal electroretinogram - OCT examination - OCT-angiography examination - retinography Primary endpoint. - central retinal thickness, measured by OCT

NCT ID: NCT05966753 Completed - Clinical trials for Diabetic Macular Edema

Describing Patient With DME, Their Patient Journey and Disease Progression

Start date: August 3, 2023
Phase:
Study type: Observational

This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.

NCT ID: NCT05961007 Suspended - Clinical trials for Diabetic Macular Edema

Evaluation of IBI302 Injection in nAMD or DME

Start date: November 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.

NCT ID: NCT05959304 Not yet recruiting - Clinical trials for Diabetic Macular Edema

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

Start date: May 31, 2024
Phase:
Study type: Observational

The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab. This study is being conducted as part of the post-marketing regulatory commitment to the Indian Health authority.

NCT ID: NCT05940428 Not yet recruiting - Clinical trials for Diabetic Macular Edema

A Study of ASKG712 in Patients With Diabetic Macular Edema

Start date: July 30, 2023
Phase: Phase 1
Study type: Interventional

This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema (DME).

NCT ID: NCT05930561 Recruiting - Clinical trials for Diabetic Retinopathy

4D-150 in Patients With Diabetic Macular Edema

Start date: August 9, 2023
Phase: Phase 2
Study type: Interventional

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

NCT ID: NCT05919693 Recruiting - Clinical trials for Diabetic Macular Edema (DME)

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

AMARONE
Start date: June 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of EYE103 will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

NCT ID: NCT05916391 Recruiting - Clinical trials for Diabetic Macular Edema

Gene Therapy for Diabetic Macular Edema

Start date: May 19, 2023
Phase: Phase 1
Study type: Interventional

FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic macular edema is the main cause of vision loss in patients with diabetic retinopathy. In the latest guidelines, anti-VEGF therapy is preferred for CI-DME. Administration of FT-003 has the potential to treat CI-DME by providing intraocular protein which is durable expressed in therapeutic level. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with CI-DME receiving anti-VEGF therapy in clinical practice.

NCT ID: NCT05885503 Recruiting - Clinical trials for Diabetic Macular Edema

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

Start date: June 8, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.